148 related articles for article (PubMed ID: 20450911)
21. [The discovery of an antiparkinsonian drug, zonisamide].
Murata M
Rinsho Shinkeigaku; 2010 Feb; 50(2):67-73. PubMed ID: 20196486
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of zonisamide in a case of Parkinson's disease with intractable resting and re-emergent tremor.
Iijima M; Osawa M; Kobayashi M; Uchiyama S
Eur J Neurol; 2011 Apr; 18(4):e43-4. PubMed ID: 21159065
[No Abstract] [Full Text] [Related]
23. Response to comment by Juan Segura-Aguilar: New preclinical model are required to discover neuroprotective compound in Parkinson's disease.
Mattace Raso G; Avagliano C; Calignano A
Pharmacol Res; 2017 May; 119():491-492. PubMed ID: 27890814
[No Abstract] [Full Text] [Related]
24. Selegiline's neuroprotective capacity revisited.
Riederer P; Lachenmayer L
J Neural Transm (Vienna); 2003 Nov; 110(11):1273-8. PubMed ID: 14628191
[No Abstract] [Full Text] [Related]
25. Recent advances in Parkinson's disease.
Vécsei L
Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
[No Abstract] [Full Text] [Related]
26. Effects of zonisamide on the electroencephalogram of a patient with juvenile myoclonic epilepsy.
Szaflarski JP
Epilepsy Behav; 2004 Dec; 5(6):1024-6. PubMed ID: 15582856
[TBL] [Abstract][Full Text] [Related]
27. Siagoside. GM1, Sygen.
Drugs R D; 1999 Jan; 1(1):36-7. PubMed ID: 10565981
[No Abstract] [Full Text] [Related]
28. Antiepileptic activity of zonisamide on hippocampal CA3 neurons does not depend on carbonic anhydrase inhibition.
Supuran CT
Epilepsy Res; 2008 Nov; 82(1):109; author reply 110. PubMed ID: 18760906
[No Abstract] [Full Text] [Related]
29. Modulation of endoplasmic reticulum stress in Parkinson's disease.
Tsujii S; Ishisaka M; Hara H
Eur J Pharmacol; 2015 Oct; 765():154-6. PubMed ID: 26297973
[TBL] [Abstract][Full Text] [Related]
30. [Effect of zonisamide on resting tremor resistant to antiparkinsonian medication].
Nakanishi I; Kohmoto J; Miwa H; Kondo T
No To Shinkei; 2003 Aug; 55(8):685-9. PubMed ID: 13677302
[TBL] [Abstract][Full Text] [Related]
31. [Discovery of an antiparkinsonian drug: zonisamide].
Murata M
Rinsho Shinkeigaku; 2010 Nov; 50(11):780-2. PubMed ID: 21921440
[TBL] [Abstract][Full Text] [Related]
32. Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy.
Peters DH; Sorkin EM
Drugs; 1993 May; 45(5):760-87. PubMed ID: 7686468
[TBL] [Abstract][Full Text] [Related]
33. Zonisamide: newer antiepileptic agent with multiple mechanisms of action.
Biton V
Expert Rev Neurother; 2004 Nov; 4(6):935-43. PubMed ID: 15853520
[TBL] [Abstract][Full Text] [Related]
34. Zonisamide in patients with essential tremor and Parkinson's disease.
Bermejo PE
Mov Disord; 2007 Oct; 22(14):2137-8. PubMed ID: 17853481
[No Abstract] [Full Text] [Related]
35. Effect of zonisamide co-administration with levodopa on global gene expression in the striata of rats with Parkinson's disease.
Ueda Y; Tokashiki S; Kanemaru A; Kojima T
Biochem Biophys Res Commun; 2012 Nov; 428(3):401-4. PubMed ID: 23103374
[TBL] [Abstract][Full Text] [Related]
36. Possible neuroprotective therapy for Parkinson's disease.
Ogawa N
Acta Med Okayama; 1995 Aug; 49(4):179-85. PubMed ID: 7502677
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures.
Baulac M; Leppik IE
Epilepsy Res; 2007 Jul; 75(2-3):75-83. PubMed ID: 17553670
[TBL] [Abstract][Full Text] [Related]
38. Disease-Modifying Drugs in Parkinson's Disease.
Park A; Stacy M
Drugs; 2015 Dec; 75(18):2065-71. PubMed ID: 26581672
[TBL] [Abstract][Full Text] [Related]
39. Introduction to zonisamide.
Baulac M
Epilepsy Res; 2006 Feb; 68 Suppl 2():S3-9. PubMed ID: 16413170
[TBL] [Abstract][Full Text] [Related]
40. Zonisamide for the treatment of Parkinson's disease.
Miwa H
Expert Rev Neurother; 2007 Sep; 7(9):1077-83. PubMed ID: 17868006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
